Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Attovia TherapeuticsATTO -2.38%8 Equity-to-Asset is 0.88 as of Jun. 2026. GuruFocus rates ATTO with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Attovia Therapeutics ranks worse than 92.49% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Attovia Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $112.77 Mil. Attovia Therapeutics's Total Assets for the quarter that ended in Jun. 2026 was $128.35 Mil.
Therefore, Attovia Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.88.
The historical rank and industry rank for Attovia Therapeutics's Equity-to-Asset or its related term are showing as below:
ATTO'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.65 Med: -0.63 Max: -0.61
Current: -0.65
During the past 2 years, the highest Equity to Asset Ratio of Attovia Therapeutics was -0.61. The lowest was -0.65. And the median was -0.63.
ATTO's Equity-to-Asset is ranked worse than 92.49% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs ATTO: -0.65
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Attovia Therapeutics Equity-to-Asset Related Terms
Attovia Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Attovia Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Attovia Therapeutics Equity-to-Asset Chart
Attovia Therapeutics Annual Data
Trend
Dec24
Dec25
Equity-to-Asset
0.81
0.91
Attovia Therapeutics Quarterly Data
Mar25
Jun25
Mar26
Jun26
Equity-to-Asset
-
-
0.91
0.88
ATTO vs TBPH, ACRS, OLMA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Attovia Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Attovia Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Attovia Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Attovia Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Attovia Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Attovia Therapeutics (ATTO) has a Equity-to-Asset of 0.88 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Attovia Therapeutics and its competitors. According to the industry distribution chart, Attovia Therapeutics ranks #1306 out of 1412 companies in the Biotechnology industry, placing it in the top 92.5%.
Is Attovia Therapeutics' Equity-to-Asset too high?
Attovia Therapeutics' current Equity-to-Asset is 0.88. The Biotechnology industry median Equity-to-Asset is 0.69. Attovia Therapeutics' value of 0.88 is 27.5% above this industry median. Based on the distribution chart, Attovia Therapeutics ranks #1306 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Attovia Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Attovia Therapeutics' Equity-to-Asset compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Attovia Therapeutics ranks #1306 out of 1412 companies for Equity-to-Asset. This places Attovia Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Attovia Therapeutics' value of 0.88 is 27.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Attovia Therapeutics's current Equity-to-Asset of 0.88 is 27.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Attovia Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Attovia Therapeutics's current Equity-to-Asset is 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Attovia Therapeutics stock overvalued right now?
Attovia Therapeutics (ATTO) has a current Equity-to-Asset of 0.88. The current Equity-to-Asset is 0.88 and 27.5% above the Biotechnology industry median of 0.69. Attovia Therapeutics' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Attovia Therapeutics (ATTO), the current Equity-to-Asset is 0.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
8GF Score
Get the complete analysis for ATTO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATTO has been successfully added to your 
